All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

New Data Shed Light on the Efficacy of BTK Inhibitors in the CLL Treatment Paradigm

October 21st 2024

David C. Fisher, MD, discusses the evolving role of BTK inhibitors in the CLL treatment paradigm.

Telisotuzumab Adizutecan Represents a Novel c-Met–Targeting ADC in MET-Amplified CRC

October 21st 2024

John H. Strickler, MD, highlights the mechanism of action of telisotuzumab adizutecan and the rationale for targeting c-Met in colorectal cancer.

Markman’s Take: Vibostolimab in dMMR Endometrial Cancer, Adjuvant Chemo in Cervical Cancer, and More

October 21st 2024

For more first-hand insights, head over to our YouTube channel to watch Dr Markman discuss the inner workings of oncology: https://rb.gy/bvumdn.

Frontline Tislelizumab/Chemo Approaches EU Approval for Gastric/GEJ Adenocarcinoma and ESCC

October 21st 2024

The European Medicines Agency has recommended extended authorization for frontline tislelizumab plus chemotherapy for GEJ adenocarcinoma and ESCC.

FDA Accepts NDA Resubmission for First-Line Rivoceranib/Camrelizumab Combo in Unresectable HCC

October 21st 2024

The FDA has accepted the new drug application resubmission for the first-line combination of rivoceranib plus camrelizumab in unresectable HCC.

FDA Approves IDH1/2+ Companion Diagnostic for Vorasidenib in Grade 2 Astrocytoma or Oligodendroglioma

October 21st 2024

The Ion Torrent Oncomine Dx Target Test received regulatory approval as a companion diagnostic to identify patients who are eligible for vorasidenib.

Fox Chase Cancer Center Researchers Find Gene That Triggers Immune Response in Treatment-Resistant Small-Cell Lung Cancer

October 21st 2024

Research from Fox Chase Cancer Center has shown that the gene TREX1 is linked to small cell lung cancer.

Optimizing Training for Future Clinical Trial Investigators

October 21st 2024

Faculty at Washington University School of Medicine in St. Louis have designed a clinical trial development fellowship education program.

New Global Hematology Journal Strives to Feature Innovative and Adaptable Research

October 21st 2024

Jorge Cortes, MD, inaugural editor-in-chief of Blood Global Hematology, details what type of research the new journal will highlight and its importance.

National Fellows Forum Showcases Next Generation of Lung Cancer Clinicians

October 20th 2024

Oncology fellows with aspirations of entering the lung cancer field gathered in Chicago, Illinois, to share findings from their research, network, and participate in panel discussions featuring expert faculty

The OncFive: Top Oncology News and Trends for the Week of 10/13

October 19th 2024

Zolbetuximab wins approval for CLDN18.2-positive gastric/GEJ cancer, TTFields joins the NSCLC armamentarium, and more of this week's top news in oncology.

Diversity Strengthens Fellowship Training and Cancer Care

October 19th 2024

Jerome D. Winegarden, MD, discusses the importance of recruiting international students to such programs.

Long-Term IO-IO Data Contest the Role of Frontline TKIs in Advanced RCC

October 18th 2024

Alan Tan, MD, discusses the nuances of navigating combination regimens for patients with advanced renal cell carcinoma.

FDA Approves Zolbetuximab Plus Chemo for CLDN18.2+ Gastric or GEJ Adenocarcinoma

October 18th 2024

The FDA approved zolbetuximab plus chemotherapy for advanced, CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma.

Botensilimab Plus Balstilimab Elicits Durable Responses in Refractory Metastatic Sarcoma

October 18th 2024

Breelyn Wilky, MD, discusses updated efficacy and safety findings following treatment of botensilimab and balstilimab in refractory metastatic sarcoma.

Gilead to Withdraw US Indication for Sacituzumab Govitecan in Metastatic Urothelial Cancer

October 18th 2024

Gilead will voluntarily withdraw the United States indication for sacituzumab govitecan in metastatic urothelial cancer.

Ribociclib Earns Positive CHMP Opinion in HR+/HER2– Early Breast Cancer

October 18th 2024

The CHMP issued a positive opinion recommending the approval of ribociclib plus endocrine therapy in HR+/HER2– early breast cancer at high risk of recurrence.

Selinexor Receives Approval in South Korea for Multiple Myeloma

October 18th 2024

The South Korean Ministry of Food and Drug Safety approved selinexor plus bortezomib and dexamethasone for pretreated patients with multiple myeloma.

The New Era of Clinical Trial Design

October 18th 2024

Jill Gilbert, MD, highlights a recent landmark decision by the FDA concerning trial design moving forward for cancer drugs.

Atrium Health Levine Cancer Begins Treating Patients with Proton Beam Therapy

October 18th 2024

Atrium Health Levine Cancer will begin treating patients with proton beam therapy.